870 Shares in Axon Enterprise, Inc $AXON Bought by Yeomans Consulting Group Inc.

Yeomans Consulting Group Inc. bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, Holdings Channel.com reports. The firm bought 870 shares of the biotechnology company’s stock, valued at approximately $675,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC raised its position in shares of Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after acquiring an additional 611,418 shares during the last quarter. Nuveen LLC acquired a new stake in Axon Enterprise during the 1st quarter valued at approximately $264,796,000. Westfield Capital Management Co. LP raised its holdings in Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. Vanguard Group Inc. raised its holdings in Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Finally, Axiom Investors LLC DE acquired a new position in shares of Axon Enterprise in the 1st quarter worth approximately $93,088,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $720.53 on Friday. The business has a 50-day simple moving average of $758.18 and a 200 day simple moving average of $706.15. Axon Enterprise, Inc has a one year low of $403.16 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The firm has a market capitalization of $56.56 billion, a price-to-earnings ratio of 177.91, a PEG ratio of 27.62 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the completion of the sale, the director owned 1,416 shares in the company, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the transaction, the chief financial officer owned 93,592 shares in the company, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,932 shares of company stock worth $37,978,216 in the last quarter. Insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AXON. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Raymond James Financial reissued an “outperform” rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Piper Sandler assumed coverage on Axon Enterprise in a research report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 target price on the stock. Finally, UBS Group reaffirmed a “neutral” rating and set a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.